What happened with HBIO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Harvard Bioscience supplies systems that help laboratories study cells and tissues and test how potential drugs affect living organisms. Pharmaceutical and biotechnology companies, contract research organizations, universities and government laboratories pay for its equipment, software, consumables and related services. Most sales go directly to end users, with distributors accounting for the rest. Consumables and software together generate more than half of revenue.
Its two product families contribute broadly similar amounts of revenue, with Preclinical the larger business. Preclinical systems collect and analyze physiological and behavioral data for drug development, safety testing and regulatory compliance. Cellular and Molecular (CMT) tools support cell, molecular and organoid research, as well as bioproduction and laboratory testing. These include MeshMEA, which measures electrical activity in organoids used for cardiac and neurological research.
Purchasing depends heavily on drug developers’ research budgets and financing, and on government funding for academic and public laboratories, rather than on any single customer. U.S. export controls apply to a small portion of its products, requiring authorization for some transactions and restricting sales to certain destinations or parties.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Harvard Bioscience also depends on preclinical research spending, where its named competitors Emka Technologies, Instem and TSE Systems offer context these listed peers miss.
Bio-Rad competes with Harvard Bioscience for academic and biopharmaceutical laboratories buying cellular and molecular research instruments and consumables. Watch Bio-Rad’s Life Science sales rather than its larger Clinical Diagnostics business for clues to demand from those research customers.
Revvity competes with Harvard Bioscience to sell research instruments, software and services to drug developers, including pharmaceutical and biotechnology companies and firms that conduct research for them. Its Life Sciences business serving these customers is the part to watch, rather than diagnostics sold to hospitals and medical laboratories.
Thermo Fisher competes with Harvard Bioscience for academic, pharmaceutical and biotechnology customers buying laboratory products and life-science technologies. Demand from those customers is more relevant to Harvard Bioscience than Thermo Fisher’s hospital, clinical-laboratory or industrial business.
Agilent competes with Harvard Bioscience for life-science researchers buying instruments to analyze cells and biological molecules. Watch those instrument offerings: Agilent’s CrossLab consumables can sell regardless of which company’s instruments a laboratory chooses.
Danaher’s life-science businesses compete with Harvard Bioscience to supply biological researchers with technologies and products; that research-facing business is the relevant comparison, not Danaher’s whole mix of biotechnology, life sciences and diagnostics.
Cytek Biosciences, Inc. and Harvard Bioscience both depend on academic, biotechnology and contract research customers spending on cell-research equipment: Cytek sells cell-analysis systems, while Harvard Bioscience sells cellular and molecular instruments. Watch Cytek’s instrument demand separately from the recurring consumables it seeks to sell to existing instrument users.
Bruker and Harvard Bioscience both depend on biological research equipment budgets from academic and biopharmaceutical customers: Bruker sells molecular and cellular measurement instruments, while Harvard Bioscience sells cellular and preclinical research tools. Bruker’s demand from biological researchers is the useful signal, rather than its materials-science or industrial applications.
Avantor and Harvard Bioscience both feel changes in laboratory purchasing by academic and biopharmaceutical customers: Avantor distributes equipment and supplies and makes fluid-handling products, while Harvard Bioscience sells research instruments. Watch Avantor’s Laboratory Solutions business for this spending, rather than treating its bioproduction sales as the same signal.
Waters competes with part of Harvard Bioscience’s molecular-analysis portfolio by selling instruments that separate and measure sample components, along with software for their users. Watch instrument sales separately from service and support, which accounted for over 35% of Waters’ sales in 2025 and include maintaining and repairing existing instruments.
Avantor, Inc. earningsAVTR
Avantor's Laboratory Solutions business will show whether academic and biopharma customers are still buying lab supplies and equipment, a demand signal for Harvard Bioscience's research tools.
Watch sales in Avantor's Laboratory Solutions business separately from bioproduction. Strength in Laboratory Solutions would suggest that lab purchasing by academic and biopharma customers—buyers Harvard Bioscience also serves—is holding up. Weakness there, even if bioproduction grows, would point to continued pressure on those research customers' budgets.
Revvity, Inc. earningsRVTY
Revvity's Life Sciences business will show whether drug developers and research-service firms are buying more research tools, a demand signal for customers Harvard Bioscience also serves.
Watch sales in Revvity's Life Sciences business, not its hospital and medical-lab diagnostics. Growth would show that drug developers and research-service firms Harvard Bioscience also serves are still buying research tools, but it would not establish how much business Harvard Bioscience is winning. A decline would point to weaker demand among these shared customers and a potentially smaller market for research tools.
Harvard Bioscience Inc earningsThis company
Harvard Bioscience's report will show whether demand for research tools is lifting sales enough to help absorb its factory costs.
Read revenue alongside gross margin. Revenue rising while the margin holds or improves would suggest stronger demand is helping spread fixed manufacturing costs across more sales. Falling revenue with a lower margin would show that weak volume is still weighing on the business. If the two move in different directions, product mix and costs may also be affecting the margin, so revenue alone does not settle the question.
